Explore the Agenda
8:30 am Check-In & Morning Coffee
9:20 am Chair’s Opening Remarks
9:29 am Linking Different Model Data to De-Risk Oncology Therapeutic Development Across Modalities & Indications
9:30 am Optimizing Tumour Models to Empower Target Validation for IO Therapies
- Identifying and validating target orthologs in mice to ensure accurate immuneoncology efficacy studies
- Employing syngeneic and xenograft mouse models and organoid systems to study tumour growth and immune response dynamics
- Linking the data from these models to elucidate the mode of action of vaccines and guide translational strategies
10:00 am Advancing Targeted DNA Damage Therapy for Glioblastoma – From Preclinical Success to Clinical Trials
- Discussing the rationale behind applying orthotopic xenograft models to empower small molecule development to better treat glioblastoma
- Demonstrating potent anti-tumour activity of this small molecule in multiple glioblastoma models with strong blood-brain barrier penetration and favourable safety in toxicology studies
- Leveraging these preclinical findings to build a strong IND package and begin treating patients with high unmet medical need with the hope of better understanding the translational relevance of these models
10:30 am Scientific Poster Session & Morning Break
Witness some of the latest and greatest research in the tumour modelling field in this spotlight
poster session! Check out the website for T&Cs.
11:44 am Spotlighting Alternative Models Beyond Classic Mouse Models & Tumour Model Selection Rationale for Novel Modalities
11:45 am Spotlighting Lessons Learned to Advance ADC Development Through Preclinical Models
- Understanding the rationale behind selecting the tumour models that were employed to aid the development of ADCs
- Overcoming the challenges with uncovering the therapeutic potential of the candidate to ensuring its effective translation to the clinic
12:15 pm Modelling Epithelial Regeneration Without Tumorigenesis: Insights from Organoids & In Vivo Tumour Models
- Integration of transcriptomics, organoid platforms, and in vivo regeneration and tumour models to study the relationship between tissue repair and tumour development
- Use of spatial transcriptomics and in vivo tumour modelling to reveal hidden cellular dynamics and link experimental findings to patient data
- Consideration of the translational relevance of these models and their implications for future research
12:45 pm Lunch Break
1:44 pm Managing Investor & C-Suite Expectations with the Science to Empower Strategic Resourcing & Safeguard R&D Cost-Efficiencies
1:45 pm Mastermind Session: Balancing Science & Stakeholder Expectations: Navigating Non-Animal Testing Roadmaps in Tumour Model Strategy
- How will the new roadmaps encouraging non-animal tests from the FDA, and the UK affect your tumour model selection?
- How do you manage investor and senior-level expectations following these changes?
- Will investors continue to ask for in vivo/NHP data, or will their requirements change?
2:29 pm Building More Patient-Derived Tumour Models to Supercharge Dosing Strategies for Promising Oncology Therapies
2:30 pm Navigating Model Selection Challenges in ADC Research: From Target Validation to Toxicity Assessment
- Discussing the rationale behind selecting human cell lines in immune-deficient mice (CDX and PDX) to evaluate ADCs targeting human-origin antigens
- Addressing the lack of robust models for predicting bone marrow and hematologic toxicity during early-stage development
- Exploring insight from platform validation experiments on efficacy, pharmacokinetics, and optimising model selection for translational success